Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin

被引：9

作者：

Bates, SM

Weitz, JI

机构：

[1] Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, Hamilton, ON L8V 1C3, Canada

[2] McMaster Univ, Hamilton, ON, Canada

来源：

CARDIOVASCULAR RESEARCH | 1999年 / 41卷 / 02期

基金：

英国医学研究理事会;

关键词：

coronary ischemic syndromes; thrombosis; anticoagulants; thrombin inhibitors; antiplatelet therapy; heparin; low-molecular-weight heparin; hirudin;

D O I：

10.1016/S0008-6363(98)00323-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：418 / 432

页数：15

共 127 条

[71] ANTIPLATELET ANTIBODY [7E3 F(AB')2] PREVENTS RETHROMBOSIS AFTER RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR-INDUCED CORONARY-ARTERY THROMBOLYSIS IN A CANINE MODEL [J].